跳到正文
原文
MedPage Today·· 17 天前精选AI 评分65

晚期镰状细胞病研究在主要目标上意见分歧

Late-Stage Sickle Cell Disease Study Splits on Main Goals

AI 导读

在RISE UP试验中,mitapivat提高了血红蛋白反应率,但未能显著减少疼痛发作。该试验支持扩大批准,但未能达到主要目标。mitapivat在减少溶血标志物和输血负担方面表现出改善,但在疲劳方面没有改善。

推荐理由

研究显示mitapivat在提高血红蛋白水平方面有效,但在减少疼痛发作方面未见显著效果。

正文

— Mitapivat improved hemoglobin response, but no significant benefit for pain crises

November 2, 2026 • 4 min read

  • Mitapivat (Aqvesme), an oral pyruvate kinase activator, is approved by the FDA for alpha- and beta-thalassemia and carries a boxed warning over the risk for liver injury.
  • In this phase III trial of sickle cell disease, mitapivat met one of its two primary endpoints.
  • Mitapivat improved rates of hemoglobin response but failed to significantly reduce the incidence of sickle cell pain crises.

The thalassemia drug mitapivat (Aqvesme) significantly improved hemoglobin response in patients with sickle cell disease but failed to top placebo when it came to reducing pain crises in a phase III trial that aims to support an expanded approval.

In the RISE UP trial, 41% of patients assigned to the oral pyruvate kinase activator had a hemoglobin response, as compared with 3% of placebo recipients (P<0.0001). But that didn't translate into a reduction in the annualized rate of sickle cell pain crises (2.6 for mitapivat vs 3.1 for placebo, P=0.1213), reported researchers led by Biree Andemariam, MD, of the New England Sickle Cell Institute at University of Connecticut Health in Farmington.

Beyond those two primary endpoints, treatment with mitapivat was associated with improved markers of hemolysis, reduced transfusion burden, and additional clinical benefits in the subset of patients with a hemoglobin response, but not with improvements in patient-reported fatigue, the study authors wrote in The Lancet.

These mitapivat data, which are currently under review with the FDA, arrive amid turbulence in the drug market for sickle cell disease. Crizanlizumab (Adakveo), approved in 2019, lost its marketing authorization in Europe after randomized trial data showed the drug failed to top placebo when it came to vaso-occlusive crises, though it's still available in the U.S.

And voxelotor (Oxbryta), which was granted accelerated approval, also in 2019, was pulled from global markets after trial data turned up an imbalance in deaths and acute vaso-occlusive crises for patients on the hemoglobin S polymerization inhibitor.

Mitapivat is currently approved as a disease-modifying treatment for anemia in adults with alpha- or beta-thalassemia, and an approval decision in sickle cell disease is expected by February of next year.

Labeling for mitapivat includes a boxed warning due to the risk of liver injury, which also warranted a risk evaluation and mitigation strategy (REMS) program. The FDA has requested an analysis on whether a REMS would be needed in sickle cell disease, but drugmaker Agios Pharmaceuticals said the data so far have shown no cases of liver injury that follow the pattern or severity seen in the thalassemia trials.

The RISE UP trial was conducted across 69 sites in 15 countries and randomized 207 patients older than 16 years with anemia and recurrent sickle cell pain crises in a 2:1 ratio to twice-daily mitapivat (100 mg) or placebo.

At baseline, participants had a median age of 25 years, 57.5% were female, mean hemoglobin was about 8.5 g/dL, and they averaged 3.4 sickle cell pain crises per year.

The primary endpoint of hemoglobin response was defined as a 1 g/dL or greater increase in average hemoglobin concentration from week 24 to week 52 compared with the baseline.

In a commentary accompanying the study, Jennifer Knight-Madden, MBBS, PhD, and Zachary Ramsay, MBBS, both of the University of the West Indies in Kingston, Jamaica, noted that despite the mixed results on the primary endpoints, "there could be clinical benefit" among the mitapivat responders.

The findings should be interpreted with caution, they noted, but post-hoc analyses suggested the mitapivat-treated participants "who achieved a hemoglobin response experienced lower annualized rates of sickle cell pain crises, fewer related hospitalizations and emergency department visits, longer times to first and second sickle cell pain crises, and lower fatigue scores compared with non-responders."

"The findings provide evidence that a clinically meaningful benefit can exist within a subset of patients," they wrote. "As acknowledged by the authors, this study was not designed to identify patients likely to achieve a hemoglobin response, and differences in hemoglobin response could be due to genetic and epigenetic modifiers, red cell metabolic differences, and co-inherited red cell variants."

As for safety data, mitapivat was associated with lower rates of grade ≥3 adverse events (AEs), at 33% versus 41% with placebo, and lower rates of serious AEs (20% vs 29%), Andemariam and colleagues reported. One of the serious AEs in a mitapivat-treated patient was considered treatment-related, however.

Overall, AEs leading to treatment discontinuation occurred in 4% of patients in the mitapivat group and in 3% of the placebo group. Despite no signal of liver injury in the study, some hepatic-related AEs did lead to mitapivat discontinuation, including one patient with increases in aspartate aminotransferase (grade 3) and bilirubin (grade 2), another patient with hepatic enzyme increases (grade 4) deemed unrelated to treatment, a patient with hepatic cytolysis (grade 2) and other AEs, and one patient with transaminase increases (grade 2) considered secondary to an infection.

Deaths occurred in 2% of the mitapivat arm and 3% of the placebo arm, with none deemed treatment-related.

来源:MedPage Today · medpagetoday.com